AI will soon master biology, unleashing new safety risks: Tencent AI chief
Tencent's AI chief warns that AI will soon master biology, creating new safety risks, while experts debate whether rapid AI-designed vaccines can overcome public distrust.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Tencent's AI chief has warned that artificial intelligence will soon master biology, unleashing new safety risks, according to the South China Morning Post. The warning comes as major technology companies pour hundreds of millions of dollars into AI-powered biodefense programs designed to compress the timeline between pathogen detection and medical countermeasure deployment. OpenAI launched a dedicated biodefense program in May that includes investment in AI-designed antibodies against novel pathogens, while Biohub, joined by Meta, Google DeepMind, and federal agencies, announced in October a $1.8 billion public-private partnership with the goal of conducting computer-based biological experiments. The World Health Organization announced a target in October to detect novel pathogens within 24 hours of emergence by 2030. Companies such as Valthos, which received $30 million in a funding round led by the OpenAI Startup Fund, are building AI systems to rapidly characterize biological sequences and update medicines in real time, with multiple startups proposing to design vaccines and therapeutics to deploy almost instantly.
However, the Bulletin of the Atomic Scientists reports that technical success may not translate into public protection if people refuse to accept AI-enabled countermeasures. Historical precedent shows vaccination campaigns can falter even with safe, effective products. The COVID-19 mRNA vaccine rollout plateaued at around 70 percent of the US population receiving the complete primary series, below the 85 percent Anthony Fauci estimated was needed for herd immunity. Demand for updated COVID formulations has since collapsed, and vaccine fatigue now extends to routine childhood immunizations. Survey research indicates less than four in 10 Americans would accept a CDC-recommended vaccine for bird flu, a disease that has only occasionally infected humans. Three factors undermine trust in novel vaccines: novelty carries a confidence penalty that trusted messengers cannot close; confidence rarely returns once lost, as shown by Japan's HPV vaccine suspension that dropped rates from 70 percent to under 1 percent with no full recovery after a decade; and acceptance suffers when speed outpaces evidence of harm, as with the 1976 swine flu campaign where rare side effects became the dominant narrative after the anticipated outbreak never materialized. Experts argue that philanthropic and technical funders must expand their definition of success beyond speed and experimental endpoints to include social infrastructure such as pre-bunking misinformation and leveraging trusted local messengers.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 8d ago.
Quick answers
What specific warning did Tencent's AI chief give about AI and biology?
Tencent's AI chief warned that AI will soon master biology, unleashing new safety risks, according to the South China Morning Post.
How much money are major tech companies investing in AI biodefense programs?
OpenAI launched a dedicated biodefense program in May, while Biohub, Meta, Google DeepMind, and federal agencies announced a $1.8 billion public-private partnership in October. Valthos received $30 million from the OpenAI Startup Fund.
Why might the public reject AI-designed vaccines even if they are technically effective?
Historical evidence shows novelty carries a confidence penalty, trust rarely returns once lost (as with Japan's HPV vaccine), and acceptance suffers when deployment speed outpaces visible evidence of harm (as with the 1976 swine flu campaign). Less than four in 10 Americans would accept a CDC-recommended bird flu vaccine.
Coverage (9)
- AI will soon master biology, unleashing new safety risks, Tencent AI chief warns SCMP · 9d ago
- Tencent AI Chief Won’t Say Hunyuan Stays Open If It Leads FourWeekMBA · 9d ago
- Sentinel Bio's Joshua Monrad: A $1 Million Lab Study Is the Wrong Way to Measure AI's Bioweapons Risk BigGo Finance · 9d ago
- AI’s next act: medical miracle or biological disaster? The Telegraph · 9d ago
- Editorial: Buck’s plan for AI guardrails sets right tone Marin Independent Journal · 9d ago
- Tencent AI chief warns models will soon pose biology risks, SCMP reports The Next Web · 9d ago
- AI could help make new vaccines. Will people take them? Bulletin of the Atomic Scientists · 9d ago
- Thank You for Attending OODAcon 2026: Escape Velocity OODA Loop · 9d ago
- AI will soon master biology, unleashing new safety risks: Tencent AI chief South China Morning Post · 9d ago
Topics
Related trends
A High-Dose Flu Vaccine Is Linked to Nearly 55% Lower Alzheimer's Risk
New scientific findings reveal a potential connection between the high-dose influenza vaccine and a significantly lower risk of developing Alzheimer's disease.
U.S. loses measles-elimination status, erasing a landmark public health achievement
The United States has officially lost its measles elimination status after 26 years, according to the Pan American Health Organization.
Measles cases nationwide top 5,400 as outbreaks spread across the US
The United States has lost its measles elimination status after 26 years following a historic resurgence that has sickened thousands.
Protecting babies from RSV during the holiday season
Health experts urge parents to protect infants from RSV as holiday gatherings and seasonal upticks approach.
Alibaba, Tencent shares fall on report U.S. weighs curbs on remote AI chip access
Alibaba and Tencent shares fell on Wednesday after reports that the U.S. is weighing curbs on Chinese companies' remote access to Nvidia AI chips.
CDC chief says agency will not change measles response if US loses elimination status
The United States faces the potential loss of its measles elimination status amid mounting nationwide deaths and ongoing outbreaks.